.
Search
Atrial fibrillation affects up to 70% of patients with ATTR-CM—but how does it impact treatment outcomes?
Dr. Brett Sperry and Dr. C. Michael Gibson discuss new findings showing that acoramidis delivered consistent clinical benefits regardless of […]
When we think of CT angio we usually think of risk stratification, prevention and diagnosis.
But CT angio can also be used to plan your PCI procedures ! Dr. Evan Shlofmitz and Dr. C. Michael […]
Dr. Ahmad Masri and Dr. C Michael Gibson discuss outpatient worsening heart failure in transthyretin amyloid cardiomyopathy in the Attribute-CM trial
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Eugene Brailovsky and Dr. C. Michael Gibson discuss: AF Outcomes and Cardiac Conduction Abnormalities In ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Steve Nissen and Dr. C. Michael Gibson discuss how management is evolving beyond statins alone—highlighting earlier combination therapy, lower LDL-C goals, and expanded roles for non-statin therapy
Sponsored by Esperion Therapeutics Inc., who did not influence the content of the presentation